Lv61
2320 积分 2025-06-04 加入
Tumor molecular age acceleration is associated with early progression in diffuse large B-cell lymphoma
27天前
已完结
Phase 1 Trial of BCL-2 Inhibitor Lisaftoclax (APG-2575) in Chinese Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Other Non-Hodgkin Lymphomas
1个月前
已完结
Venetoclax plus azacitidine in relapsed or refractory T-cell acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 trial
2个月前
已完结
Evaluation of the Impact of Monitoring for Tumor Lysis During Venetoclax Ramp-Up in Chronic Lymphocytic Leukemia in Routine Clinical Practice
3个月前
已完结
Letermovir Prophylaxis for CMV DNAemia /Disease after HLA ‐Mismatched HSCT : A Retrospective Real‐World Analysis with Overlap Propensity Score Weighting
3个月前
已完结
Letermovir Prophylaxis for CMV DNAemia /Disease after HLA ‐Mismatched HSCT : A Retrospective Real‐World Analysis with Overlap Propensity Score Weighting
3个月前
已完结
Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: predictive impact of early blast reduction on the remission status after induction
4个月前
已完结
Venetoclax or Pirtobrutinib in Relapsed/Refractory Waldenström Macroglobulinemia: Clinical and Molecular Predictors and Sequencing Implications
4个月前
已完结
Anticancer efficacy of 3-(4-isopropyl) benzylidene-8-ethoxy, 6-methyl, chroman-4-one (SBL-060), a novel, dual, estrogen receptor-Akt kinase inhibitor in acute myeloid leukemia cells
6个月前
已完结
Dual mTORC1/2 Inhibition Synergistically Enhances AML Cell Death in Combination with the BCL2 Antagonist Venetoclax
6个月前
已完结
皖公网安备34019202002308
